低抗凝肝素可破坏新鲜临床分离株中的恶性疟原虫玫瑰花结。
Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates.
作者信息
Leitgeb Anna M, Blomqvist Karin, Cho-Ngwa Fidelis, Samje Moses, Nde Peter, Titanji Vincent, Wahlgren Mats
机构信息
Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden.
出版信息
Am J Trop Med Hyg. 2011 Mar;84(3):390-6. doi: 10.4269/ajtmh.2011.10-0256.
Abstract
The binding of Plasmodium falciparum parasitized erythrocytes to uninfected erythrocytes (rosetting) is associated with severe malaria. The glycosaminoglycan heparan sulfate is an important receptor for rosetting. The related glycosaminoglycan heparin was previously used in treatment of severe malaria, although abandoned because of the occurrence of severe bleedings. Instead, low anticoagulant heparin (LAH) has been suggested for treatment. LAH has successfully been evaluated in safety studies and found to disrupt rosettes and cytoadherence in vitro and in vivo in animal models, but the effect of LAH on fresh parasite isolates has not been studied. Herein, we report that two different LAHs (DFX232 and Sevuparin) disrupt rosettes in the majority of fresh isolates from Cameroonian children with malaria. The rosette disruption effect was more pronounced in isolates from complicated cases than from mild cases. The data support LAH as adjunct therapy in severe malaria.
摘要
恶性疟原虫寄生的红细胞与未感染红细胞的结合（形成花结）与严重疟疾相关。糖胺聚糖硫酸乙酰肝素是花结形成的重要受体。相关的糖胺聚糖肝素曾被用于治疗严重疟疾，尽管因发生严重出血而被弃用。取而代之的是，有人建议使用低抗凝肝素（LAH）进行治疗。LAH已在安全性研究中成功得到评估，并发现其在动物模型的体外和体内均能破坏花结和细胞黏附，但LAH对新鲜寄生虫分离株的作用尚未得到研究。在此，我们报告两种不同的LAH（DFX232和舍普帕肝素）能破坏来自喀麦隆疟疾患儿的大多数新鲜分离株中的花结。花结破坏效应在复杂病例的分离株中比在轻症病例中更为明显。这些数据支持LAH作为严重疟疾的辅助治疗方法。
相似文献
1
Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates.低抗凝肝素可破坏新鲜临床分离株中的恶性疟原虫玫瑰花结。
Am J Trop Med Hyg. 2011 Mar;84(3):390-6. doi: 10.4269/ajtmh.2011.10-0256.
2
Effects of sevuparin on rosette formation and cytoadherence of Plasmodium falciparum infected erythrocytes.舍曲肝素对恶性疟原虫感染红细胞的玫瑰花结形成和细胞黏附的影响。
PLoS One. 2017 Mar 1;12(3):e0172718. doi: 10.1371/journal.pone.0172718. eCollection 2017.
3
Disruption of Plasmodium falciparum erythrocyte rosettes by standard heparin and heparin devoid of anticoagulant activity.标准肝素和无抗凝活性肝素对恶性疟原虫红细胞玫瑰花结的破坏作用。
Am J Trop Med Hyg. 1992 May;46(5):595-602. doi: 10.4269/ajtmh.1992.46.595.
4
Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with Plasmodium falciparum malaria.在恶性疟原虫疟疾患者中，塞肝素对裂殖子入侵的抑制作用及短暂的脱隔离作用
PLoS One. 2017 Dec 15;12(12):e0188754. doi: 10.1371/journal.pone.0188754. eCollection 2017.
5
Release of sequestered malaria parasites upon injection of a glycosaminoglycan.注射一种糖胺聚糖后被隔离的疟原虫的释放。
PLoS Pathog. 2006 Sep;2(9):e100. doi: 10.1371/journal.ppat.0020100.
6
Plasmodium falciparum: molecular background to strain-specific rosette disruption by glycosaminoglycans and sulfated glycoconjugates.恶性疟原虫：糖胺聚糖和硫酸化糖缀合物对菌株特异性玫瑰花结破坏的分子背景
Exp Parasitol. 1999 Feb;91(2):133-43. doi: 10.1006/expr.1998.4349.
7
Molecular mechanisms and biological importance of Plasmodium falciparum erythrocyte rosetting.恶性疟原虫红细胞玫瑰花结形成的分子机制及生物学重要性
Mem Inst Oswaldo Cruz. 1992;87 Suppl 3:323-9. doi: 10.1590/s0074-02761992000700054.
8
Rosette formation in Plasmodium falciparum isolates and anti-rosette activity of sera from Gambians with cerebral or uncomplicated malaria.恶性疟原虫分离株中的玫瑰花结形成以及患有脑型疟疾或非重症疟疾的冈比亚人血清的抗玫瑰花结活性。
Am J Trop Med Hyg. 1992 May;46(5):503-10. doi: 10.4269/ajtmh.1992.46.503.
9
Erythrocyte rosetting in Plasmodium falciparum malaria--with special reference to the pathogenesis of cerebral malaria.恶性疟原虫疟疾中的红细胞玫瑰花结形成——特别提及脑型疟疾的发病机制
Scand J Infect Dis Suppl. 1993;86:1-79.
10
Fresh isolates from children with severe Plasmodium falciparum malaria bind to multiple receptors.来自患有严重恶性疟原虫疟疾儿童的新鲜分离株可与多种受体结合。
Infect Immun. 2001 Sep;69(9):5849-56. doi: 10.1128/IAI.69.9.5849-5856.2001.
引用本文的文献
1
Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy.多面肝素：抗凝治疗之外的多样应用
Pharmaceuticals (Basel). 2024 Oct 12;17(10):1362. doi: 10.3390/ph17101362.
2
SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART).SEVUparin作为重症疟疾儿童潜在辅助治疗方法：一项I期安全性和剂量探索试验（SEVUSMAART）。
Wellcome Open Res. 2024 Aug 12;8:484. doi: 10.12688/wellcomeopenres.20111.2. eCollection 2023.
3
Therapeutics through glycobiology: an approach for targeted elimination of malaria.通过糖生物学进行治疗：一种靶向消除疟疾的方法。
Biologia (Bratisl). 2023 Jan 10:1-5. doi: 10.1007/s11756-023-01312-x.
4
Red Blood Cells Oligosaccharides as Targets for Plasmodium Invasion.红细胞低聚糖作为疟原虫入侵的靶点。
Biomolecules. 2022 Nov 11;12(11):1669. doi: 10.3390/biom12111669.
5
Vascular Dysfunction in Malaria: Understanding the Role of the Endothelial Glycocalyx.疟疾中的血管功能障碍：了解内皮糖萼的作用。
Front Cell Dev Biol. 2021 Nov 10;9:751251. doi: 10.3389/fcell.2021.751251. eCollection 2021.
6
Antiparasitic Effects of Sulfated Polysaccharides from Marine Hydrobionts.海洋生物源硫酸多糖的抗寄生虫作用。
Mar Drugs. 2021 Nov 12;19(11):637. doi: 10.3390/md19110637.
7
Repurposing Heparin as Antimalarial: Evaluation of Multiple Modifications Toward In Vivo Application.将肝素重新用作抗疟药：针对体内应用的多种修饰的评估。
Pharmaceutics. 2020 Aug 29;12(9):825. doi: 10.3390/pharmaceutics12090825.
8
translational machinery condones polyadenosine repeats.翻译机制容忍多聚腺苷酸重复。
Elife. 2020 May 29;9:e57799. doi: 10.7554/eLife.57799.
9
Non-Anticoagulant Heparins as Heparanase Inhibitors.非抗凝肝素作为乙酰肝素酶抑制剂。
Adv Exp Med Biol. 2020;1221:493-522. doi: 10.1007/978-3-030-34521-1_20.
10
Plasmodium falciparum histidine rich protein HRPII inhibits the anti-inflammatory function of antithrombin.恶性疟原虫富含组氨酸的蛋白HRPII抑制抗凝血酶的抗炎功能。
J Thromb Haemost. 2020 Jun;18(6):1473-1483. doi: 10.1111/jth.14713. Epub 2020 Jan 14.
本文引用的文献
1
var gene transcription dynamics in Plasmodium falciparum patient isolates.恶性疟原虫患者分离株中的基因转录动态
Mol Biochem Parasitol. 2010 Apr;170(2):74-83. doi: 10.1016/j.molbiopara.2009.12.002. Epub 2009 Dec 16.
2
Disruption of rosetting in Plasmodium falciparum malaria with chemically modified heparin and low molecular weight derivatives possessing reduced anticoagulant and other serine protease inhibition activities.
J Med Chem. 2008 Mar 13;51(5):1453-8. doi: 10.1021/jm701337t. Epub 2008 Feb 9.
3
In vitro inhibition of Plasmodium falciparum rosette formation by Curdlan sulfate.硫酸凝结多糖对恶性疟原虫玫瑰花结形成的体外抑制作用。
Antimicrob Agents Chemother. 2007 Apr;51(4):1321-6. doi: 10.1128/AAC.01216-06. Epub 2007 Feb 5.
4
Differential changes in Plasmodium falciparum var transcription during adaptation to culture.恶性疟原虫var转录在适应培养过程中的差异变化。
J Infect Dis. 2007 Mar 1;195(5):748-55. doi: 10.1086/511436. Epub 2007 Jan 22.
5
Generation of cross-protective antibodies against Plasmodium falciparum sequestration by immunization with an erythrocyte membrane protein 1-duffy binding-like 1 alpha domain.通过用红细胞膜蛋白1-达菲结合样1α结构域免疫产生针对恶性疟原虫隔离的交叉保护性抗体。
Infect Immun. 2007 Jan;75(1):211-9. doi: 10.1128/IAI.00749-06. Epub 2006 Oct 30.
6
Release of sequestered malaria parasites upon injection of a glycosaminoglycan.注射一种糖胺聚糖后被隔离的疟原虫的释放。
PLoS Pathog. 2006 Sep;2(9):e100. doi: 10.1371/journal.ppat.0020100.
7
Whole-body imaging of sequestration of Plasmodium falciparum in the rat.恶性疟原虫在大鼠体内隐匿情况的全身成像。
Infect Immun. 2005 Nov;73(11):7736-46. doi: 10.1128/IAI.73.11.7736-7746.2005.
8
Curdlan sulphate in human severe/cerebral Plasmodium falciparum malaria.
Trans R Soc Trop Med Hyg. 2005 May;99(5):333-40. doi: 10.1016/j.trstmh.2004.05.005.
9
Heparan sulphate identified on human erythrocytes: a Plasmodium falciparum receptor.在人类红细胞上鉴定出的硫酸乙酰肝素：一种恶性疟原虫受体。
Biochem J. 2004 Aug 1;381(Pt 3):593-7. doi: 10.1042/BJ20040762.
10
Cross-sectional study of specific antibodies to a polymorphic Plasmodium falciparum antigen and of parasite antigen genotypes in school children on the slope of Mount Cameroon.喀麦隆山山坡上学龄儿童中针对多态性恶性疟原虫抗原的特异性抗体及寄生虫抗原基因型的横断面研究。
Trans R Soc Trop Med Hyg. 2004 May;98(5):284-9. doi: 10.1016/S0035-9203(03)00068-3.
Zotero 插件